Results 61 to 70 of about 1,816 (169)
Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy
BMEMat, Volume 3, Issue 1, March 2025.This review provides a brief overview of several of the major, and potentially life‐threatening, toxicities associated with CAR T cell therapies and discusses various examples of the genetic and chemical engineering strategies employed to effectively mitigate such toxicities in preclinical models and clinical studies. Abstract Chimeric antigen receptor
Tyler Wolter, Yixin Wang, Quanyin Hu
wiley +1 more source
MethodsX, 2019 A rapid HILIC-MS method was developed for measuring the genotoxic impurities aziridine and 2-chloroethylamine. Sample preparation was simple and direct without requiring derivatization.
Jonathan G. Shackman
doaj +1 more source
New Insights Into Hepatic Impairment (HI) Trials
Clinical and Translational Science, Volume 18, Issue 1, January 2025.ABSTRACT Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into the data from dedicated HI studies, cluster these data into various categories and connect the effect by ...
Sebastian Haertter +4 more
wiley +1 more source
Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
, 2015 Asunaprevir (ASV), an isoquinoline-based competitive inhibitor targeting the hepatitis C virus (HCV) NS3/4A protease, is very potent in vivo. However, the potency is significantly compromised by the drug resistance mutations R155K and D168A.
Celia A. Schiffer (148545) +2 more
core +1 more source
, 2020 Introduction: Hepatitis C virus (HCV) is estimated to infect approximately 70 million people worldwide. If left untreated, chronic infection can progress to cirrhosis, liver failure or hepatocellular carcinoma. The advent of new direct-acting antivirals (
Zappulo E. +5 more
core +1 more source
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015 The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver ...
M. V. Mayevskaya +2 more
doaj
Case Reports in Gastroenterology, 2017 Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b.
Kazuo Tarao, Akira Sato
doaj +1 more source
Chemogenetic Tools in Focus: Proximity, Conformation, and Sterics
Chemistry–Methods, Volume 4, Issue 6, June 2024.Chemogenetic tools have been widely applied to interrogate dynamic biological processes. They are genetically encoded systems that are controlled by user‐defined chemicals. In this review, chemogenetic tool designs for various biological applications are introduced and discussed.
Jiaqi Shen, Guanwei Zhou, Wenjing Wang
wiley +1 more source
Liver International, Volume 44, Issue 5, Page 1075-1092, May 2024.Abstract Background and Aims The beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached.
Annalisa Cespiati +6 more
wiley +1 more source
Viruses, 2015 Sustained virological response (SVR) rates have increased dramatically following the approval of direct acting antiviral (DAA) therapies. While individual DAAs have a low barrier to resistance, most patients can be successfully treated using DAA ...
Kazuaki Chayama, C. Nelson Hayes
doaj +1 more source